Using artificial tears without success?
Cequa increases tear production in dry eye disease (DED) patients. It’s delivered via nanomicellar (NCELL) technology, which helps to improve the bioavailability and physicochemical stability of cyclosporine.
Cequa is made for the long-term treatment of DED. It addresses the inflammatory component of the disease by helping patients produce more tears that last longer and tears that are healthier. Cequa also helps patients produce more tears over time and improves the health of the ocular surface.